MMSI

Business Context and Reporting Period

Company: Merit Medical Systems, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: Merit Medical Systems develops, manufactures, and markets disposable medical products primarily for the diagnosis and treatment of cardiovascular disease. Key product lines include inflation devices, angiographic catheters, guidewires, and custom kits. The company operates manufacturing facilities in the United States (Utah, Texas, California) and Ireland, with sales distributed globally.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. EPS figures are diluted.

Material Changes vs. Prior Period

• Revenue Growth: Sales increased by $19.7 million (17%), driven by a 19% increase in stand-alone product revenues and an 18% increase in custom kit revenues. International sales grew 27% to $34.3 million (25% of total sales), aided by a favorable Euro exchange rate.
• Margin Expansion: Gross margin improved by 300 basis points to 44.7%, attributed to operational efficiency, productivity gains ($118,000 sales per employee), and favorable currency effects.
• Profitability Surge: Net income rose 53% to $17.3 million. This was supported by higher gross profits, SG&A expenses decreasing as a percentage of sales (22.4% vs 23.9%), and a $1.4 million gain in "Other Income" (including a $508k gain on land sale and $475k legal settlement).
• Liquidity Strengthening: Cash position more than tripled to $30.2 million. The company paid down its revolving credit facility entirely and reduced long-term debt to zero.
• Stock Splits: The company executed two 4-for-3 stock splits in 2003 (August and December), adjusting historical share data.

Guidance, Outlook, and Risks

Management Commentary & Outlook

• Capital Expenditures: Management anticipates significant investment in 2004, estimating approximately $26 million for facility expansions in South Jordan, Utah (103% increase) and Galway, Ireland (151% increase), plus $5 million for new production equipment.
• Product Strategy: Continued focus on sensor-based technologies, catheters, and guide wires. R&D expenses are expected to range between 3% and 4% of net sales in 2004.
• Margin Expectations: Management anticipates maintaining or slightly improving gross margins in 2004 despite a generally declining price market.

Risks and Contingencies

• Product Liability & Recalls: Inherent risk of product failure or design defects leading to recalls or lawsuits. The company maintains $5 million in liability insurance.
• Regulatory Compliance: Subject to FDA regulations; failure to comply could adversely affect operations.
• Concentration Risk: Inflation devices accounted for approximately 33% of total revenues in 2003. A decline in demand for these specific products could materially impact results.
• Key Personnel: CEO Fred P. Lampropoulos announced his candidacy for Governor of Utah in January 2004. The company has no key man life insurance on him.
• Foreign Exchange: Approximately 9.6% of sales were denominated in Euros. A decline in the Euro/Dollar rate could negatively impact financial results.

Investor Verification Checklist

• Capital Expenditure Execution: Verify the timeline and cost management of the planned $31 million in facility expansions and equipment upgrades for 2004.
• CEO Availability: Monitor the impact of the CEO's gubernatorial campaign on company leadership and strategic focus.
• Product Mix Dependency: Assess the sustainability of revenue growth given the 33% reliance on inflation devices and potential market obsolescence from new medical technologies.
• Stock-Based Compensation: Note that reported net income does not reflect stock-based compensation costs under SFAS 123; pro forma net income for 2003 would be approximately $14.3 million.
• International Exposure: Review the impact of Euro exchange rate fluctuations on future margins, as 25% of sales are international.